The Effect of Paraprotein on Platelet Aggregation by Đunić, Irena et al.
Journal of Clinical Laboratory Analysis 28: 141–146 (2014)
The Effect of Paraprotein on Platelet Aggregation
Irena Djunic,1∗ Ivo Elezovic,1,3 Vesna Ilic,2,3 Nadezda Milosevic-Jovcic,2,3 Jelena Bila,1,3
Nada Suvajdzic-Vukovic,1,3 Darko Antic,1 Ana Vidovic,1,3 and Dragica Tomin1,3
1Clinic for Hematology, Clinical Center of Serbia, Belgrade, Serbia
2Institute for Medical Research, Belgrade, Serbia
3School of Medicine, University of Belgrade, Belgrade, Serbia
Background: Some patients with parapro-
teinemia have platelet aggregation disor-
ders and the aim of this study was to
examine disturbance of platelet aggrega-
tion in healthy blood donors by isolated
paraprotein in vitro. Methods: Using Ri-
vanol, paraprotein was separated from the
serum of ten patients with paraproteine-
mia, who had decreased platelet aggre-
gation with several inducers. Platelet ag-
gregation in ten healthy donors was mea-
sured with and without addition of the iso-
lated induced paraprotein. The test was re-
peated with added human immunoglobu-
lins for intravenous use. Results: Average of
maximal levels of platelet aggregation has
been significantly decreased in plasma rich
in platelets (PRP) of healthy donors after
addition of paraprotein when inducers are
used: adenosine diphosphate (ADP) (P =
0.007), collagen (COL) (P = 0.008), risto-
cetin (RIS) (P = 0.001), and epinephrine
(EPI) (P = 0.002). Average of latent time of
platelet aggregation was significantly pro-
longed in healthy donors after addition of
paraprotein with inducers: COL (P = 0.008),
RIS (P = 0.008) and EPI (P = 0.006)
while addition of human immunoglobulins
caused no change in platelet aggregation.
In comparison, when human immunoglob-
ulins were added, maximal platelet aggre-
gation and latent time did not change sig-
nificantly. Paraprotein isolated from patients
with paraproteinamia, who had decrease
platelet aggregation, had significantly de-
creased platelet aggregation when added to
PRP of healthy donors, in vitro. Conclusion:
Platelet aggregation was not significantly
changed was confirmed with addition of hu-
man immunoglobulins. J. Clin. Lab. Anal.
28:141–146, 2014. C© 2014 Wiley Periodi-
cals, Inc.
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INTRODUCTION
Paraproteins are immunoglobulins synthesized and se-
creted by neoplastically transformed B-cell lines (lympho-
cytes and plasma cells) (1). Paraproteins are also known
as M-component, which refers to malignant gammaglob-
ulinemia in myeloma and macroglobulinemia (2). Since
they are products of uncontrolled cell proliferation, their
blood level is very high and they are detected as elec-
trophoretically homogenous fractions, which can be dis-
tinguished from normal serum immunoglobulins (3).
Paraproteins with normal immunoglobulin structure
are macromolecules consisting of four polypeptide chains,
two of which are short (light (L) chains) and two are long
(heavy (H) chains) (4, 5). Immunoglobulins have a 3D
space structure characterized by the presence of globu-
lar unit domains. These are formed by specific wrapping
of consecutive homologous segments, composed of 110
amino acids and interconnected by intrachain disulfide
bonds (6). Each light chain has two globular domains
and each heavy chain has four or five globular domains
(7). The basic functional unit is an entirely symmetric
globular molecule composed of 12 or 14 domains (6, 7).
The immunoglobulins are divided into five classes on
the basis of differences between heavy chain domains. The
five classes are immunoglobulins M (IgM) with μ heavy
chains, immunoglobulins G (IgG) with γ heavy chains, im-
munoglobulins A (IgA) with α heavy chains, immunoglob-
ulins E (IgE) with ε heavy chains, and immunoglobulins D
(IgD) with δ heavy chains. IgG consists of four subclasses
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or isotypes (IgG1, IgG2, IgG3, IgG4), and IgA consists of
two subclasses (IgA1, IgA2). There are two types of light
chains: kappa (κ) and lambda (λ). Each immunoglobulin
isotype has both κ and λ chains, but a single molecule
can be either κ or λ. Approximately two-thirds of the
immunoglobulins have κ-type domains (κ/λ ratio— 2:1)
(8, 9).
Paraproteins appear as molecules missing certain
polypeptide chains, or their parts, as well as hybrid
molecules with a variety of oligosaccharide chains, or as
molecules with subtle changes without visible effects on
the global structure. Structural alterations occur in both
light and heavy chains of the paraproteins, as a conse-
quence of genetic (deletions, insertions, conversions, point
mutations) or posttranslational changes (10–14).
The most important physicochemical property of para-
proteins is electrophoretic homogeneity, which is due to
the identical electrical charge of the molecules enormously
produced by an uncontrolled proliferating clone. The elec-
trophoresis graphic record registers the paraprotein as a
particular peak, the sharpness of which reflects clonal-
ity, while the intensity reflects the concentration. During
electrophoresis, paraproteins move as a compact fraction,
depending on the isotype variant of the immunoglobu-
lin. IgG and IgM paraproteins are most commonly lo-
calized in the gamma, and IgA in the β electrophoretic
field (15, 16). The carbohydrate component, interconnec-
tion of molecules into polymers, solubility etc. influence
the electrophoretic homogeneity and rate of movement of
paraproteins. Differences in the structure of the variable
regions, by which the subclasses of light chains are deter-
mined, may lead to different electrophoretic mobility of
paraproteins with the same type of light and heavy chains
as well (3, 17).
Paraproteins often react nonspecifically with other
plasma proteins: albumin, haptoglobin, α1-glycoproteins,
complement system proteins, coagulation factors and they
can bind nonspecifically to various platelet receptors. The
following are the most common hemostatic disorders—
prolonged bleeding time, decreased platelet adhesion,
impaired platelet aggregation, prolonged prothrombotic
time (PT) and partial thromboplastin time (PTT), low
concentrations of factors V, VII, VIII, and X, prothrom-
bin, fibrinogen, and total protein. Moreover, paraprotein
can inhibit factor VIII and vWF, or act as a lupus an-
ticoagulant (3, 18–21). The aim of this research was to
examine the role of paraprotein in platelet aggregation
disorder in patients with paraproteinemia.
PATIENTS AND METHODS
Paraprotein was isolated from ten nontreated patients
with paraproteinemia, nine of them with the diagnosis
of multiple myeloma, while one patient had monoclonal
gammopathy of undetermined significance (MGUS).
Platelet aggregation disorder was established for all ten
patients. Thus, platelet aggregation was decreased with
all inducers used, but each patient had a normal platelet
count.
Five microliter blood samples from each patient were
allowed to clot, and after centrifugation the separated
serum was frozen at −70◦C. Paraproteins were extracted
from the sera, which belonged to the IgG class. Platelet
aggregation tests in plasma from healthy donors were per-
formed in vitro with and without added isolated parapro-
tein. In order to exclude the possibility of nonspecific
binding of paraproteins to the platelet receptors in vitro,
the platelet aggregation test was repeated with added im-
munoglobulins for intravenous application.
Isolation of the Paraproteins
IgG paraproteins were partially fractionated from the
serum samples by the Rivanol method. Rivanol solution
(1.5%) was added to serum in a 1:1 volume ratio. The mix-
ture was left overnight at 4◦C, and afterwards centrifuged
for 10 min at 3,000 rotations per minute (rpm). The super-
natant contained IgG (so-called Rivanol-soluble IgG) and
the protein concentration was determined by the tannin
turbidimetric method. The relative abundance of protein
fractions in the samples was determined by densitome-
try of electrophoretically separated fractions using Im-
age Quant software (San Diego, CA). A horizontal elec-
trophoresis device was used to fractionate IgG in 1% agar
gel in an electric field of 8 mA for 30–40 min. The protein
fractions were visualized by staining with amido black.
The subclass of the isolated IgG paraproteins was deter-
mined by the Western blot method. After electrophoretic
separation on agar gel, the proteins were transferred to
a nitrocellulose membrane and allowed to dry in the air.
All membranes were then incubated with mouse mon-
oclonal antibodies specific for γ1, γ2, γ3, and γ4 heavy
chains of human IgG. The characteristics of these mono-
clonal antibodies were defined in a collaborative study of
the World Health Organization. After reaction with sec-
ondary antibody (goat antibody to mouse IgG) the spots
were visualized with peroxidase using chloronaphthol as
the substrate, which, in the presence of H2O2, gives a blue-
purple precipitate (15, 22, 23).
Platelet Aggregation
Platelet aggregation was measured by Born’s optical
method, using whole blood aggregometer model 560. Ve-
nous blood was collected in a test tube containing an-
ticoagulant sodium citrate in the ratio 1:9. Plasma rich
in platelets (PRP) was obtained by centrifugation at 800
rpm for 15 min at 20◦C, while plasma poor in platelets
J. Clin. Lab. Anal.
Paraprotein and Platelet Aggregation 143
(PPP) was obtained by centrifugation at 3,000 rpm for
15 min. Light ray transience through PRP is 100%, but
through PPP it is 0% due to differing optical density of
the samples caused by the presence of many platelets in
PRP. After adding an agonist for aggregation, the opti-
cal density decreases while light transmittance increases.
The signal occurring during aggregation converts auto-
matically into an electrical impulse, which is transmitted
to the printer. A graphic record of aggregation is thus
obtained. PRP (450 μl) was poured into plastic tubes
in the presence of a magnetic stick. Platelet aggrega-
tion was determined by adding 50 μl of agonist in the
following concentrations: adenosine diphosphate (ADP)
10 μmol/l, collagen (COL) 10 μmol/l, ristocetin (RIS)
1.25 mg/ml, and epinephrine (EPI) 10 μmol/l. Aggre-
gation monitoring time was 10 min. The maximal level
of aggregation, expressed in transmission unit percentage,
was determined from the graphic record of the aggrega-
tion curve. Normal values of aggregation are 60–100%
(0.6–1.0). The latent period from the moment of adding
the agonist till the beginning of aggregation was measured
as well, where 1 sec corresponded to 1 mm on the aggrega-
tion graphic record. Cross-match between healthy control
platelets and isolated paraprotein and initially disturbed
platelet aggregation was performed as follows: First,
50 μl of 0.9% NaCl was added to 450 μl PRP from a
healthy examinee in a plastic tube. The latent period until
the beginning of aggregation and the final level of ag-
gregation were measured after incubation at 37◦C. Sub-
sequently, 50 μl of paraprotein solution isolated from a
patient with paraproteinemia and platelet aggregation dis-
order was added to 450 μl PRP from the same healthy
donor and aggregation measured in the same way. The
platelet aggregation tests were again repeated with addi-
tion of 50 μl of immunoglobulin for intravenous applica-
tion to 450 μl PRP from the ten healthy donors instead
of paraprotein (24).
Statistical Analyses
The statistical significance of differences was deter-
mined by Student’s t-test for paired samples. The mean
value (x) of the maximal level of platelet aggregation for
all examined aggregation inductors was calculated for the
healthy subjects after adding 0.9% NaCl to plasma. The
average value (X) of the maximal level of platelet aggre-
gation was also calculated after adding paraprotein to
successive samples of each examinee’s plasma for all ex-
amined aggregation inductors and the average change (y)
was determined. For all obtained parameters, the t-test
value (t) was calculated for the defined degree of freedom
(df) and P-value (P) for the average value of maximal
level of platelet aggregation, as well as the latent period.
Statistical significance was set at P < 0.05.
RESULTS
After adding isolated paraproteins to successive sam-
ples of plasma from healthy donors, the average value of
the maximal level of platelet aggregation with ADP dif-
fered from the values of 0.9% NaCl controls, t = 3.51,
df = 9, P = 0.007. In the presence of ADP, there was no
statistically significant change in average value of platelet
aggregation latent period in healthy donors between 0.9%
NaCl and isolated paraprotein. Moreover, when intra-
venous immunoglobulin was present in healthy donors’
plasma, there were no differences in average values of
latent period or maximal achieved platelet aggregation
with ADP. A comparison of the values of maximal level
of platelet aggregation of PRP with ADP directly sensed
from the graphic record of the aggregation curve between
0.9% NaCl and isolated paraproteins is shown in Figure 1.
After adding isolated paraproteins to plasma from
healthy subjects, the change in the average value of
maximal level of platelet aggregation with COL was
Fig. 1. Platelet aggregation by ADP in PRP of healthy donors before and after addition of paraprotein (P = 0.007).
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Fig. 2. Platelet aggregation by COL in PRP of healthy donors before and after addition of paraprotein (P = 0.002).
statistically significant, t = 4.233, df = 9, P = 0.002.
These results are given in Figure 2. The average value
of platelet aggregation latent period after adding para-
proteins to plasma from healthy donors in the presence
of COL was also statistically significant, t = −3.417,
df = 9, P = 0.008. With intravenous immunoglobulins
in the plasma from healthy donors, there were no signif-
icant changes either in average value of maximal level of
aggregation, or in average value of the latent period.
In the presence of RIS, the change in the average value
of maximal level of platelet aggregation after adding iso-
lated paraproteins to plasma from healthy donors was
statistically significant, t = 4.599, df = 9, P = 0.001 as
shown in Figure 3. There was also a significant change
in average value of platelet aggregation latent period in
the presence of RIS, t = −3.420, df = 9, P = 0.008. Af-
ter adding intravenous immunoglobulins to plasma from
healthy donors, there were no significant changes in the
average values of either maximal level of aggregation or
latent period.
For EPI, the mean value of maximally achieved platelet
aggregation changed significantly after adding parapro-
teins to plasma from healthy donors, in comparison to the
average value obtained with 0.9% NaCl, t = 4.382, df =
9, P = 0.002. The comparison is shown in Figure 4. In ad-
dition, a significant change in the average value of platelet
aggregation latent period with EPI also occurred, t =
−3.579, df = 9, P = 0.006. After adding intravenous im-
munoglobulins, there were no significant differences either
in mean value of maximal achieved aggregation with EPI,
or in mean value of the latent period.
DISCUSSION
Paraproteins are structurally altered immunoglobulins
synthesized by terminally differentiated B cells (lympho-
plasmocytes and plasma cells) emerging by proliferation
of a single clone (monoclone) (1, 9). Structural changes
may occur both in heavy and light chains, as well as in
the carbohydrate part of the paraprotein (8, 10, 11, 25).
Fig. 3. Platelet aggregation by RIS in PRP of healthy donors before and after addition of paraprotein (P = 0.001).
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Fig. 4. Platelet aggregation by EPI in PRP of healthy donors before and after addition of paraprotein (P = 0.002).
The main roles of oligosaccharides in the structure
of immunoglobins are determination of conformational
stability, electric charge, and solubility of the molecule,
and they are of key significance for achieving effector an-
tibody functions, principally binding to complement and
cell receptors. Moreover, they have an influence on affin-
ity, elimination, and secretion of immunoglobulins (25).
Paraproteins can also react with a number of exogenous
and endogenous antigens, as well as with nonbiological
haptens. Most paraproteins bind to structures of their own
organism (26, 27). Thus, paraproteins often show autore-
activity to Fc fragments of immunoglobulin G (rheuma-
toid factor activity), erythrocyte antigens (the activity of
cold agglutinins), cytoskeletal proteins and DNA (polyre-
active activity), and myelin glycoproteins. A paraprotein
reacts with the supposed antigen throughout its Fab frag-
ments in which antigen-binding spaces are localized (28).
The platelet function disorder occurs due to nonspecific
binding of paraproteins to the platelet surface. In that way,
receptor fields for different platelet aggregation agonists
are blocked (19, 28). Among specific paraprotein targets,
binding to the platelet glycoprotein IIIa, GPIb, as well as
direct paraprotein binding to A1 domain vWF, has been
described, which leads to disorders of platelet adhesion
and aggregation (21, 29).
In order to assess the role of paraproteins in platelet ag-
gregation disorder, we initially detected platelet aggrega-
tion disorder to the reagents ADP, COL, RIS, and EPI in a
group of patients. Before implementing therapy, we froze
the samples for isolation of paraproteins. First, platelet
aggregation with above-mentioned aggregation inductors
was performed in ten blood donors as healthy control sub-
jects. The maximal achieved aggregation curve elevation
and latent period until the beginning of aggregation were
measured. Then paraprotein was added and the maximal
achieved aggregation curve elevation and latent period
were determined again. Isolated paraprotein from each
patient had its own healthy control. Moreover, in contrast
to normal immunoglobulins, excluding the possibility of
nonspecific binding of paraproteins to platelet receptors in
vitro and demonstrating that structural changes in para-
proteins are the cause of platelet aggregation disorder;
the maximal achieved platelet aggregation and latent pe-
riod with ADP, COL, RIS, and EPI were determined for
each healthy donor before and after adding immunoglob-
ulin for intravenous application. In the presence of ADP,
COL, RIS, and EPI significant changes were found in the
average value of maximal achieved platelet aggregation af-
ter adding paraproteins to the plasma of healthy donors
in vitro. Also, there were significant alterations in the aver-
age value of platelet aggregation latent period with COL,
RIS, and EPI, but not with ADP. In contrast to this, no
significant changes were found in the average values of
maximal achieved platelet aggregation or platelet aggre-
gation latent period with any of the tested aggregation
inductors after adding immunoglobulins for intravenous
application to plasma from healthy donors in vitro.
This research has indirectly shown that paraprotein, as
a structurally aberrant immunoglobulin, may be the cause
of platelet aggregation disorder in patients with parapro-
teinemia. Its mechanism of activity is probably binding to
platelet receptors that participate in platelet aggregation.
This leads to receptor block and the impossibility of ag-
gregation agonists to bind to their specific receptors on
platelets.
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